Status:
COMPLETED
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
Lead Sponsor:
GlaxoSmithKline
Conditions:
HIV Infection
Infection, Human Immunodeficiency Virus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet o...
Detailed Description
A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in ...
Eligibility Criteria
Inclusion
- HIV infected subjects that are naive to anti-HIV therapy.
- History of a positive HIV test.
- At least 1000 copies/mL of HIV in their blood as screening.
Exclusion
- Active HIV-related diseases.
- Taking other investigational drugs.
- Pregnant or breastfeeding females.
- Not be suitable to participate per investigator opinion.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
866 Patients enrolled
Trial Details
Trial ID
NCT00085943
Start Date
May 1 2004
Last Update
May 16 2011
Active Locations (119)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35233
2
GSK Investigational Site
Phoenix, Arizona, United States, 85006
3
GSK Investigational Site
Los Angeles, California, United States, 90046
4
GSK Investigational Site
Sacramento, California, United States, 95825